SGPT

The SGPT test measures the alanine aminotransferase enzyme found in liver cells, indicating the presence of hepatocellular damage. Elevated values provide a reliable biochemical marker in the evaluation of acute or chronic liver diseases.

SGPT level analyses are used to determine the severity of liver inflammation and cellular destruction. It is particularly helpful in monitoring disease activity in hepatitis, toxic exposures, and fatty liver disease, and supports the evaluation of treatment response.

SGPT follow-up measurements are important in monitoring liver effects caused by medication use. Regular check-ups detect potential hepatotoxicity at an early stage, increasing treatment safety and providing a scientific basis for dosage adjustments.

SGPT liver function monitoring allows the assessment of liver stress caused by metabolic and systemic diseases. Trend analysis of values plays a critical role in monitoring disease progression, risk classification, and supporting long-term clinical decision-making processes.

What Is SGPT?

SGPT (Serum Glutamic Pyruvic Transaminase), also known as ALT (Alanine Aminotransferase), is an enzyme found in liver cells. In the event of liver damage, it enters the bloodstream, causing its level to rise. The SGPT test is used in the diagnosis and monitoring of liver diseases such as hepatitis, fatty liver, and drug toxicity. A high SGPT level may indicate cellular damage in the liver.

What does the SGPT (ALT) enzyme do in the body?

SGPT, or ALT, is an enzyme primarily located inside your liver cells. Its main function is to help process amino acids, the building blocks of proteins. It plays a key role in converting the proteins you consume into energy or into other molecules your body needs.

Think of it this way: your liver cells are like tiny sacs filled with the SGPT enzyme. When the cells are healthy, they keep this enzyme safely inside. But if the liver becomes stressed for any reason—such as an infection (like hepatitis), excess fat accumulation, alcohol, toxins, or certain medications—the walls of these cells become damaged. Damaged cells leak their SGPT content into the bloodstream.

This is why, when you have a blood test, an elevated SGPT level means that your liver cells are sending out a kind of “distress signal.” The higher the level in the blood, the more widespread the damage at that moment. Although SGPT is found in small quantities in the kidneys, heart, and muscle tissue, its primary home is the liver, making it a very specific marker of liver damage.

Why can SGPT values be concerning even when they are in the ‘normal’ range?

On your lab results sheet, you may see a broad “normal” or “reference” range for SGPT (ALT), typically between 7 and 56 U/L. However, especially when fertility and IVF are involved, it is crucial not to over-rely on the word “normal.”

These standard ranges are determined based on the general population and often fail to detect underlying, yet asymptomatic (subclinical), liver conditions. Detailed research shows that the “true” healthy upper limit—particularly for women—is actually much lower than these standard reference values. Some experts argue that the ideal upper limit for a woman should be around 19 U/L or 25 U/L.

What does this mean? For example, if your SGPT result is 40 U/L, it may appear “normal” on paper. However, this value may actually be an early sign of liver fat accumulation or a metabolic issue. Polycystic Ovary Syndrome (PCOS) and obesity are common among women seeking IVF treatment, and these conditions already predispose the liver to stress. Therefore, we pay close attention to these “normal on paper but above ideal” values.

Many factors should be considered when interpreting SGPT levels.

• Sex (Generally higher in men)
• Body Mass Index (SGPT tends to rise with increasing weight)
• Age
• Medications or supplements used
• Intense exercise (may cause temporary elevation due to muscle release)
• Daily rhythm (SGPT levels typically peak in the afternoon)

What is the AST/ALT ratio and how does it provide clues along with SGPT?

When assessing SGPT, we almost always examine its “sibling” enzyme AST (Aspartate Aminotransferase) as well. Although a high SGPT value alone indicates a problem, the ratio of these two enzymes (AST/ALT ratio or De Ritis ratio) acts like a detective, providing invaluable clues about the underlying cause.

Although both are liver enzymes, their locations within the cell and their concentrations in other tissues differ. This ratio helps us think of different scenarios.

If the ALT value is higher than AST (i.e., AST/ALT ratio is below 1), this is a common pattern seen in conditions such as fatty liver disease (NAFLD) or chronic viral hepatitis (Hepatitis B or C).

If AST is higher than ALT (ratio above 1), this may suggest more chronic and potentially more serious liver damage, such as advanced disease like cirrhosis.

If AST is more than twice the ALT (ratio above 2), this is a strong and classic indicator of alcohol-related liver damage. Seeing this ratio requires thoroughly questioning alcohol consumption.

What are the most common causes of elevated SGPT in women trying to conceive?

In a woman of reproductive age, especially when she seeks infertility treatment, elevated SGPT typically brings metabolic and reproductive health conditions to mind—issues that are not only liver-focused but often systemic.

The primary causes most prominent in the differential diagnosis include:

• Non-alcoholic fatty liver disease (NAFLD / SLD)
• Metabolic disorders associated with Polycystic Ovary Syndrome (PCOS)
• Viral hepatitis (Especially chronic Hepatitis B and C)
• Excessive alcohol consumption
• Drug-induced liver injury (DILI)
• Herbal supplements or “detox” products
• Autoimmune hepatitis (The body attacking its own liver cells)
• Hemochromatosis (Excess iron accumulation in the body)
• Wilson’s disease (Excess copper accumulation in the body)
• Celiac disease (Gluten sensitivity)
• Thyroid disorders
• Severe muscle injury (Even after very intense exercise)

What is the connection between Polycystic Ovary Syndrome (PCOS) and elevated SGPT?

This is the most important and frequently encountered link in IVF treatments. PCOS is one of the leading causes of infertility due to ovulation problems. Women diagnosed with PCOS are up to four times more likely to have fatty liver disease (NAFLD) compared to those without PCOS.

This is no coincidence; both conditions share a common underlying enemy: Insulin Resistance (IR).

The majority of PCOS patients (approximately 50–70%) have insulin resistance. When insulin resistance is present, the body struggles to transport sugar into the cells, and the pancreas compensates by secreting more insulin. In this chaotic environment, free fatty acids are released uncontrollably from fat tissue into the bloodstream.

These free fatty acids rush into the liver like a flood. The liver’s capacity to process this amount of fat is limited. When it cannot burn or eliminate the fat, it begins to store it internally as triglycerides. This is what we call fatty liver disease (NAFLD).

A fatty liver eventually becomes inflamed (steatohepatitis). As inflammation progresses and the liver cells become damaged, they release SGPT into the bloodstream.

Additionally, the excess male hormones (hyperandrogenism) and frequent coexisting obesity seen in PCOS further fuel this vicious cycle and worsen fatty liver. Therefore, elevated SGPT in an overweight or obese PCOS patient is considered part of an underlying metabolic storm.

Why is knowing the SGPT level so important before starting IVF treatment?

When we request liver function tests, including SGPT, from a couple preparing for IVF treatment, this is not merely a routine check. It is a risk assessment.

Both the hormonal medications used during IVF to stimulate egg growth (especially estrogen) and pregnancy itself place a metabolic load—a “stress test”—on the liver. If your liver is already tired at the start of treatment (i.e., fatty or with elevated SGPT), it may struggle to cope with this additional load.

Knowing the SGPT level beforehand guides us in the following:

• Predicting the patient’s susceptibility to complications such as OHSS (Ovarian Hyperstimulation Syndrome) during treatment.
• Determining whether there is an increased risk for serious liver-related complications during pregnancy, such as preeclampsia or ICP (intrahepatic cholestasis of pregnancy).

Based on these risks, we can personalize and adjust the treatment protocol (for example, applying a “freeze-all” strategy).

Providing the patient with accurate information about potential risks and planning pregnancy follow-up more closely.

Does existing liver disease or elevated SGPT affect IVF success?

This is the question our patients are most concerned about: “Will this liver issue prevent the embryo from implanting?”

The evidence is quite clear and reassuring. The answer is largely “No.”

A large study comparing women with chronic liver disease (CLD) to healthy women revealed the following:

• The CLD group had fewer eggs retrieved due to factors such as age and weight.
• Fewer eggs retrieved resulted in fewer embryos.
• However (and this is the key point) the quality of the retrieved eggs was the same.
• Fertilization rates were the same.
• The rates of genetically normal (euploid) embryos were also identical.

The most striking finding was this: When a single genetically normal (euploid) embryo was transferred, there was no statistical difference between the liver-disease group and healthy group in pregnancy rates, miscarriage rates, or live birth rates.

This means: Having a stable (compensated) liver condition or elevated SGPT does not affect the potential of a healthy embryo to implant.

Our concern lies not with implantation but with two other areas:

• Cycle Efficiency: Underlying metabolic issues may result in fewer eggs or embryos per cycle.
• Pregnancy Safety: Our main worry is whether your liver can handle the load once pregnancy begins and whether serious complications such as ICP or preeclampsia may occur.

Can elevated SGPT levels affect NIPT (non-invasive prenatal testing) performed during pregnancy?

This is one of the lesser-known but extremely important indirect effects of elevated SGPT. NIPT is an advanced test that screens for chromosomal disorders such as Down syndrome using a single tube of maternal blood. The test works by analyzing fetal DNA fragments circulating in the mother’s blood.

For the test to be successful, the proportion of fetal DNA within the total cell-free DNA in the mother’s blood (called fetal fraction) must be sufficiently high.

Here is where the problem begins: If the mother’s liver is inflamed (i.e., SGPT is elevated), damaged liver cells also break down and release maternal DNA into the bloodstream. This creates a kind of “background noise.”

This maternal DNA “noise” suppresses or dilutes the fetal signal (fetal fraction). The testing device cannot clearly read the fetal DNA, and the report may return a “no call” result.

One study highlighted this risk:

• Normal SGPT + IVF pregnancy = Low test failure risk
• High SGPT (>40 U/L) + IVF pregnancy = Test failure rising up to 9.5%

This does NOT mean there is a problem with the baby; it only indicates a technical failure of the test. However, it can cause unnecessary logistical difficulties and emotional stress for the family. Therefore, informing patients with high SGPT about this possibility beforehand is crucial for managing expectations.

What steps are taken if the SGPT value is high before starting treatment?

Suppose we performed your bloodwork and found that your SGPT level is above the ideal range. There is no need to panic. We have a clear roadmap to follow.

• Step 1: Identify the Cause

First, we must determine the reason for the elevation. Alcohol consumption, prescription and over-the-counter medications, and especially herbal supplements marketed as “natural” are questioned thoroughly. Tests for viral hepatitis (Hepatitis B and C), iron and copper levels, autoimmune markers, and blood clotting function (INR) are ordered.

• Step 2: Imaging

Next, we request an abdominal ultrasound. This helps us clearly observe the liver’s structure, the presence and severity of fat accumulation (steatosis), and any signs of advanced damage (fibrosis or cirrhosis).

• Step 3: Lifestyle Intervention and Optimization

If the cause is non-alcoholic fatty liver disease (NAFLD), which is the most common scenario, we begin an “optimization” process before initiating IVF treatment. The main therapy here is not medication but lifestyle modification.

The key lifestyle changes include:

• Switching to a Mediterranean diet
• Avoiding processed foods, sugary drinks, and packaged products
• Regular physical activity (e.g., at least 150 minutes of brisk walking per week)
• Weight control and approaching ideal body weight
• Complete cessation of alcohol
• Stopping all unnecessary medications and herbal supplements

If SGPT is very high (more than five times the upper limit of normal) or if ultrasound reveals significant findings, we always consult a liver specialist (Hepatologist or Gastroenterologist) before beginning treatment.

How is safe IVF treatment planned for patients with high SGPT or liver sensitivity?

In patients whose liver is already tired or sensitive, we aim to prevent IVF treatment from placing an additional burden or triggering complications. Our ultimate goal for this group is “maximum safety.”

One of the biggest risks in IVF treatment is OHSS (Ovarian Hyperstimulation Syndrome). OHSS itself can significantly impair liver function. PCOS patients with fatty liver are also among the highest-risk groups for OHSS.

To prevent this combined risk, we follow three golden rules:

• Use of an antagonist protocol (provides more controlled and safer stimulation)
• “Agonist trigger” (avoiding hCG-containing trigger injections and almost eliminating OHSS risk)
• “Freeze-all” strategy

The “Freeze-all” strategy is crucial for this patient group. This means: We retrieve the eggs, create embryos in the laboratory, and freeze all healthy embryos. No fresh transfer is performed that month.

This way, we wait for the body to exit the hormonal storm completely, for the ovaries to return to normal, and—most importantly—for the liver to rest. One or two months later, when the body is fully calm, we transfer your frozen embryo into a much safer and more natural uterine environment. This approach eliminates OHSS risk entirely and removes the acute metabolic load on the liver.

Why is SGPT monitoring important for Intrahepatic Cholestasis of Pregnancy (ICP) that appears during pregnancy?

IVF pregnancies require closer monitoring in certain aspects compared to naturally conceived pregnancies. The liver is one of the key organs in this close monitoring process.

Research shows that women who conceive through IVF have almost three times higher risk of developing a pregnancy complication called Intrahepatic Cholestasis of Pregnancy (ICP).

The suspected reason is that the high doses of estrogen and progesterone used during IVF treatment (both for stimulation and for luteal support) may slow or disrupt bile flow in the liver.

The main symptom of ICP is itching. Its typical features include:

• It starts especially on the palms and soles
• It becomes unbearable at night
• It usually does not present with a visible rash

When a pregnant IVF patient comes in with this itching complaint, we immediately order a blood test. We check not only SGPT but especially serum bile acids. SGPT may rise even before bile acids and can serve as our first warning sign.

ICP is usually just an annoying but harmless condition for the mother; however, it is serious for the baby. High bile acids pose the following risks to the baby:

• Spontaneous preterm birth
• Meconium passage (baby pooping in the womb)
• Acute fetal distress (baby becoming compromised)
• The most feared: sudden stillbirth

Therefore, we take this diagnosis very seriously. Medication (Ursodeoxycholic acid – UDCA) is started to reduce bile acids, and depending on bile acid levels, delivery is carefully planned between 36 and 39 weeks to minimize risk.

How is elevated SGPT related to Preeclampsia and HELLP syndrome?

Another serious pregnancy condition involving the liver is preeclampsia.

IVF pregnancies unfortunately carry a higher risk of preeclampsia compared to spontaneous pregnancies. This risk is slightly higher if frozen embryo transfer is performed in a medicated (programmed) cycle.

Preeclampsia is new-onset high blood pressure after the 20th week of pregnancy, accompanied by organ damage. The liver is one of the target organs affected. Elevated SGPT and AST levels are among the most important warning signs that preeclampsia has become “severe” and has begun to affect the liver.

The most feared complication of preeclampsia is HELLP syndrome, a life-threatening condition. HELLP is named after three findings:

• Hemolysis (Breakdown of red blood cells)
• EL (Elevated Liver Enzymes)
• LP (Low Platelets)

In HELLP syndrome, due to widespread liver damage, SGPT levels may rise to 200–700 IU/L or even higher. This is a medical emergency for both mother and baby, carrying risks such as placental abruption, stroke, liver rupture, and maternal or fetal death. The only definitive treatment, regardless of gestational age, is immediate delivery.

What should patients with elevated SGPT expect during this process?

Putting all this information together shows why SGPT is not just a simple blood test during IVF treatment, but rather a navigation tool.

If your SGPT level is high or if you have underlying fatty liver, this does not prevent you from having a baby. It simply means we need to prepare before beginning the journey—optimizing your metabolic health as much as possible. Reducing SGPT with lifestyle changes (diet, exercise, weight control) before treatment improves both the number of eggs retrieved (cycle efficiency) and, more importantly, the safety of your pregnancy.

Once you achieve a pregnancy through IVF, you should expect closer monitoring than in a “normal” pregnancy. You must be especially attentive to symptoms such as itching in the second half of pregnancy, severe headaches, visual disturbances, or pain in the upper abdomen—these can be early signs of ICP or preeclampsia and must be reported immediately.

SGPT should be viewed not as an obstacle but as a “signal” from your body. Reading this signal correctly and managing the process accordingly creates the safest path toward holding a healthy baby in your arms.

Frequently Asked Questions